NASDAQ: RANI - Rani Therapeutics Holdings, Inc.

Rentabilité sur six mois: -70.01%
Secteur: Healthcare

Calendrier des promotions Rani Therapeutics Holdings, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies.

Plus de détails
Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company was incorporated in 2012 and is headquartered in San Jose, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Выручка 0.000979
EBITDA -0.0261
Число акций ао 0.02551 млрд
P/S 4296.54
P/BV -43.53
EV/EBITDA -165.09
Цена ао 3.18
ISIN US7530181004
Сайт https://www.ranitherapeutics.com
Валюта usd
IPO date 2021-07-30
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Changement de prix par jour: 0% (2.12)
Changement de prix par semaine: -9.79% (2.35)
Changement de prix par mois: -10.55% (2.37)
Changement de prix sur 3 mois: -37.09% (3.37)
Changement de prix sur six mois: -70.01% (7.07)
Changement de prix par an: +5.47% (2.01)
Evolution du prix sur 3 ans: -86.82% (16.09)
Evolution des prix depuis le début de l'année: +5.47% (2.01)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 3.31 5
P/E 0 0
EV/EBITDA -1.65 0
Total: 3.13

Efficacité

Nom Signification Grade
ROA, % -58.65 0
ROE, % -264.03 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.4611 10
Total: 7.8

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 175.79 10
Rentabilité Ebitda, % 150.1 10
Rentabilité EPS, % -6.2 0
Total: 6.6
Plus de détails

Établissements Volume Partager, %
Vanguard Group Inc 668347 2.57
Nan Fung Group Holdings Limited 493584 1.9
United Services Automobile Association 481300 1.85
Alphabet Inc. 448492 1.72
Bank of America Corporation 114259 0.44
Geode Capital Management, LLC 113629 0.44
Blackrock Inc. 63583 0.24
Lasry, Marc 62887 0.24
Alpha Square Group S, LLC 58946 0.23
King Luther Capital Management 56129 0.22

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
Dimensional International Core Equity 2 ETF 0.00033 17.713295799047 3.69996
Dimensional International Small Cap ETF 0.00065 18.692449355433 3.34747
Dimensional International Small Cap Value ETF 0.00059 18.789944610141 4.55441



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Mir A. Imran Executive Chairman 80k 1956 (68 années)
Mr. Talat Imran CEO & Director 450k 1982 (42 année)
Mr. Svai S. Sanford Chief Financial Officer 416k 1970 (54 année)
Dr. Mir Hashim Chief Scientific Officer 416k 1960 (64 année)
Mr. Eric Groen General Counsel N/A 1971 (53 année)
Ms. Bella Vazquez Vice President of Human Resources N/A
Ms. Kate McKinley M.B.A. Chief Business Officer N/A 1977 (47 années)
Ms. Arvinder Dhalla Vice President of Clinical Development N/A

Adresse: United States, San Jose. CA, 2051 Ringwood Avenue - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.ranitherapeutics.com